eliquis apixaban eliquis apixaban eliquis apixaban

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, click here.

For Prescribing and Adverse Event reporting information, click here.

eliquis (apixaban) a factor xa inhibitor image 2 LEARN MORE eliquis (apixaban) a factor xa inhibitor image 5 LEARN MORE
patient with doctor image

ELIQUIS is indicated for the prevention of stroke / systemic embolism in patients with NVAF and one or more risk factors (such as prior stroke or transient ischaemic attack, age ≥ 75 years, hypertension, diabetes mellitus, symptomatic heart failure [New York Heart AssociationClass ≥ II]) 1

EXPLORE DATA IN NVAF
patient image

Eliquis is indicated for the treatment of DVT / PE and prevention of recurrent DVT / PE 1

EXPLORE DATA IN DVT / PE
patient with doctor image 3

Now is the time to offer your patients ELIQUIS

GO TO DOSING AND SWITCHING
Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.
Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
SmPC = Summary of Product Characteristics

ELIQUIS (apixaban) is an oral, direct factor Xa inhibitor indicated for prevention of stroke / systemic embolism in adult patients with NVAF, with one or more risk factors (such as prior stroke or transient ischaemic attack, age ≥ 75 years, hypertension, diabetes mellitus, symptomatic heart failure [New York Heart Association Class ≥ II]), treatment of DVT and PE, and prevention of recurrent DVT and PE in adults.1

Reference:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.

bristol myers squibb logo

© 2021 Bristol-Myers Squibb Pharmaceuticals Limited

All corporate names and logos of BMS and/or of its products are trademarks of Bristol-Myers Squibb Company and are protected by national and international intellectual and industrial property laws. All rights reserved over the content of this website.

Your use of this website is subject to the Legal Notice, the Privacy and Cookie Policy, the Pharmacovigilance Notice and the applicable laws and regulations.

432-GB-2100219
Date of preparation May 2021